Opinion
Video
Author(s):
Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.
Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Revisit the OncLive On Air Episodes From February 2024
Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion
Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer
Liso-Cel Associated With Improved Benefit in Earlier Lines of Therapy in R/R Mantle Cell Lymphoma
Zanubrutinib Plus Venetoclax Generates 100% ORR in Treatment-Naive Del17p/TP53+ CLL/SLL
Ide-Cel Generates Favorable PFS Outcomes in R/R Multiple Myeloma With Lower Tumor Burden
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies